Drug Profile

Olanzapine/samidorphan - Qilu Pharmaceutical

Latest Information Update: 17 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Qilu Pharmaceutical
Class Amides; Antipsychotics; Benzodiazepines; Cyclopropanes; Mood stabilisers; Morphinans; Oxazepines; Phenanthrenes; Small molecules; Thiazepines
Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 5-HT2A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Clinical Phase Unknown Schizophrenia

Most Recent Events

17 Dec 2024 Chemical structure information added.
21 Oct 2024 Clinical trials in Schizophrenia (PO) before October 2024 (NCT06649214)
21 Oct 2024 Qilu Pharmaceutical plans a phase III trial for Schizophrenia in November 2024 (PO) (NCT06649214)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com